FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
What happened
FDA inspected Medline Industries, LP's drug manufacturing facility at 1710 South Lakeside Drive, Waukegan, Illinois, from October 6 to 14, 2025. FDA said the firm found Bacillus cereus (B. cereus), a bacterium, in finished drug product samples about nine times from June 2, 2023 to August 27, 2025 and in at least five manufacturing environment samples since January 2025. FDA cited these as current good manufacturing practice (CGMP) violations and said Medline did not adequately investigate the repeated contamination or correct root causes.
What FDA found
FDA said Medline did not thoroughly investigate repeated Bacillus cereus contamination in finished drug samples and the manufacturing environment or fix the root cause.
21 CFR 211.192FDA said Medline lacked adequate separate or defined areas, controls to prevent contamination or mix-ups, and operations in areas of adequate size.
21 CFR 211.42(c)FDA said Medline did not establish and follow adequate written procedures for cleaning and maintenance of equipment.
21 CFR 211.67(b)FDA said operators used cleaning tools without suitable gloves and then repeatedly touched drug product, and the firm identified objectionable aseptic (contamination-controlled) behaviors as a root cause of contamination.
21 CFR 211.42(c)FDA said operators routinely deviated from procedures for cleaning and disinfecting equipment, including valves, and the firm identified inadequate cleaning as a root cause of Bacillus cereus contamination.
21 CFR 211.67(b)FDA cited similar CGMP observations at other facilities in the company network, including inadequate investigations into out-of-specification results at Hartland, Wisconsin, showing inadequate management oversight.
What FDA wants
FDA tells Medline to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence; if it cannot finish, it must give reasons and a completion schedule. FDA also asks for independent assessments and remediation plans for contamination hazards, cleaning and disinfection, sterilization options, investigations, corrective actions, and aseptic practices.
Who should pay attention
- drug manufacturers with cleanroom operations
- companies that buy or distribute Medline drug products
- quality teams handling microbial contamination and investigations
This is a summary. Read the original letter on fda.gov.